Facilitate Collaborate Innovate

You are here

Non-Horizon 2020

The Innovative Medicines Initiative (IMI2) is a public-private partnership run jointly by the European Union and the pharmaceutical industry association, EFPIA. The IMI2 aims to support research projects and build networks of industrial and academic experts to boost pharmaceutical innovation in Europe. The IMI2 website gives further details about its aims, structure and funding opportunities.

News:

Forthcoming Innovative Medicines Initiative (IMI) topics

IMI Stakeholder Forum 2016 - Presentations Available

Innovative Medicines Initiative (IMI) has launched Calls 11 and 12.

EuropeAid is responsible for designing EU development policies and delivering aid through programmes and projects across the world in order to reduce poverty, ensure sustainable development and promote democracy, good governance and respect of human rights.  Further information on what the EuropeAid does can be found on their website.  Please also see information on funding opportunities.

The Third health programme 'Health for Growth' is the main instrument the European Commission uses to implement the EU health strategy.  It aims to support and complement the work of European Member States to achieve the following four objectives: developing innovative and sustainable health systems; increasing access to better and safer healthcare for EU citizens; to prevent diseases and promote good health; and protecting citizens from cross-border health threats. The health programme is managed by the Commission with the assistance of the Consumers, Health and Food Executive Agency (Chafea).

European Research Area (ERA)-NET Cofunds are to support the preparation, establishment of networking structures, design, implementation and coordination of joint actives of public-public partnerships, but there is an increased move towards  topping up of single joint calls in selected areas relevant for H2020. ERA-NETS are a combination of EC and member-state specific funding (e.g. RCUK), so the costing (X5) element is handled by the Research Services divisional teams (i.e. Med-Sci, Hum-Soc and Parks Road). Information on ERA-NETS can be found on the ERA website; each ERA-NET call bid is issued separately.

DG Home Affairs. This is the Directorate-General (lead by commissioner Cecilia Malmström) dealing in policy that aims at ensuring economic, cultural and social growth of the EU that will lead to a more stable, lawful and secure environment (and an open and safer Europe) - please visit the DG Home affairs website for more details. Policies fail into two areas: EU internal security and migration and asylum. The current UK related policies and applicable tenders can be found on the funding pages.

The European and developing Countries Clinical Trials Partnership (EDCTP), which was established in 2003, aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria, with focus on phase II and III clinical trials in sub-Saharan Africa. Together these three diseases account for over 3.5 million deaths each year. The EDCTP website gives further details on their strategy, funding opportunities and contact details.

News & Events:

The European & Developing Countries Clinical Trials Partnership (EDCTP) has released its 2017 Work Plan containing a number of research funding opportunities likely to be of interest to some Oxford academics.

The Active and Assisted Living Programme (AAL), which was set up in 2007, aims to support industry, in particular SMEs (Small and Medium-sized Enterprises) to bring digital innovative products and services for ageing well to the European market. Further information is available on the AAL website and the AAL is proposed to continue for the period 2014-2020.

The European Innovation Partnership on Active and Healthy Ageing (EIP AHA) is a European initiative which brings together a range of stakeholders interested in prevention and health promotion, care and cure, and active and independent living of elderly people. Ultimately it aims to increase the average healthy lifespan by two years by 2020. Further information on what the EIP AHA is and what it does, including any funding opportunities are available on the EIP AHA website.

The LIFE (the financial instrument for the environment) programme offers funding for Climate Action and the Environment with a general objective to contribute to the implementation, updating and development of EU environmental and climate policy and legislation by co-financing projects with European added value. The majority of the LIFE programme is run by the Executive Agency for Small and Medium-sized Enterprises (EASME). For full informaiton on the programme and funding opportunities see the LIFE website.

News & Events:

LIFE launches 2017 call for action grants